Presence and number of cortical lesions is associated with disease severity.
Cortical lesions are present throughout the multiple sclerosis (MS) disease course, with increased frequency in progressive MS. Investigators studied the value of cortical lesions for predicting development of secondary progressive (SP) MS in patients with relapsing remitting (RR) disease.
They enrolled 219 patients with RRMS and a mean disease duration of 8 years (range, 5–12 years). Cortical lesions (CLs) were detected in 76% of patients. Secondary progressive (SP) MS was diagnosed in 27%. SPMS was more frequent in those with a greater number of CLs. SPMS was also more prevalent in men, in patients with older age at onset, and in those who had a higher number of early exacerbations. Patients with two CLs had a twofold increased risk for de…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)